Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific shops neuro businesses

This article was originally published in The Gray Sheet

Executive Summary

Firm is reportedly exploring plans to sell its neuromodulation and neurovascular businesses. A sale of both divisions could raise about $2 billion to aid debt repayment, Wells Fargo Securities analyst Larry Biegelsen suggests in recent report. The businesses generated 2009 sales of $285 million and $348 million, respectively. The neuromodulation division is Boston Scientific's fastest growing unit, but the firm may be willing to sell "because it is falling behind" competitors Medtronic and St. Jude Medical, "and it requires significant investment to reach its growth potential," Biegelsen said. Potential neuromodulation buyers include Johnson & Johnson and Abbott, while candidates for the neurovascular biz include Medtronic, St. Jude, Bard and Covidien, according to Biegelsen. Boston Scientific said in February it planned to divest several product lines over the next two years (1"The Gray Sheet" Feb. 15, 2010)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT028747

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel